Classification
Product TypeProcessed Food
Product FormOral dietary supplement (capsules/tablets/powder)
Industry PositionFinished Consumer Supplement Product
Market
In Mexico, glucosamine is marketed in the "suplemento alimenticio" category and is regulated by COFEPRIS under the legal framework for dietary supplements. Imports of dietary supplements require a COFEPRIS Permiso Sanitario Previo de Importación (PSPI), with review focused on ingredients and labeling compliance. COFEPRIS guidance emphasizes that dietary supplements are intended only to complement dietary intake and must not be promoted as treating, curing, preventing, or alleviating disease. Market access risk is therefore driven primarily by regulatory classification, permitted ingredients, and compliant Spanish labeling.
Market RoleDomestic consumption market supplied by both imports and domestic manufacturing, with import entry controlled through COFEPRIS sanitary permitting (PSPI)
Domestic RoleConsumer supplement category subject to COFEPRIS oversight; products must be positioned as diet-complementing rather than therapeutic
Specification
Physical Attributes- Oral dosage forms (e.g., cápsulas, tabletas, polvos) are recognized by COFEPRIS as acceptable presentations for suplementos alimenticios
- Front panel labeling should include the generic denomination "SUPLEMENTO ALIMENTICIO" as specified by COFEPRIS guidance
Packaging- Retail packaging must carry compliant Spanish labeling for Mexico, including ingredient list (including excipients/additives when used) and required risk/allergen statements where applicable
Supply Chain
Value Chain- Manufacturer (domestic or foreign) → importer of record → COFEPRIS PSPI application/approval (for imports) → customs clearance → national distributor → retail and direct-to-consumer channels
Freight IntensityLow
Transport ModeMultimodal
Risks
Regulatory Compliance HighIn Mexico, dietary supplements require COFEPRIS-controlled compliance and (for imports) a Permiso Sanitario Previo de Importación (PSPI) with review of ingredients and labeling; non-compliant positioning (e.g., therapeutic claims) or labeling gaps can block entry, trigger holds, or force relabeling/withdrawal actions.Run a pre-shipment COFEPRIS compliance check: confirm product classification as suplemento alimenticio, verify permitted ingredient composition, ensure the front label includes "SUPLEMENTO ALIMENTICIO", and prepare the PSPI dossier (labels, certificates/analyses as applicable) before dispatch.
Consumer Claims MediumCOFEPRIS guidance states supplements are not intended to treat, cure, prevent, or alleviate disease; arthritis/joint-pain therapeutic claims can elevate enforcement risk and may lead to regulatory action or reclassification concerns.Align all labels, inserts, and marketing with non-therapeutic, diet-complementing language consistent with COFEPRIS supplement guidance; keep claim substantiation files ready for audits.
Food Safety MediumIf glucosamine inputs are derived from allergen-relevant sources (e.g., crustaceans), Mexico labeling expectations around risk-component disclosure and allergen declaration become critical; omissions can lead to non-compliance findings and consumer safety exposure.Document ingredient source (including allergen origin where applicable) and ensure required risk/allergen statements are present and consistent across origin and Spanish labels.
FAQ
Do glucosamine supplements need a sanitary registration in Mexico?COFEPRIS states that dietary supplements (suplementos alimenticios) do not require a sanitary registration, but manufacturers and/or responsible marketers must file an “Aviso de funcionamiento,” and imports require a COFEPRIS Permiso Sanitario Previo de Importación (PSPI).
What must the front label say for a dietary supplement sold in Mexico?COFEPRIS supplement labeling guidance specifies that the generic denomination “SUPLEMENTO ALIMENTICIO” must appear on the front panel, independent of other legends, along with other minimum labeling information.
Can a glucosamine supplement be marketed in Mexico as treating arthritis or curing joint pain?COFEPRIS guidance indicates dietary supplements are only for increasing/complementing dietary intake and are not intended to treat, cure, prevent, or alleviate disease, so therapeutic arthritis claims increase regulatory non-compliance risk.